advertisement
García-Feijoo J 17
Showing records 1 to 17 | Display all abstracts from García-Feijoo J91099 CPAMD8 loss-of-function underlies non-dominant congenital glaucoma with variable anterior segment dysgenesis and abnormal extracellular matrix
Bonet-Fernández JM
Human Genetics 2020; 139: 1209-1231
91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Konstas AG
Expert Opinion on Drug Safety 2021; 0: 1-14
91099 CPAMD8 loss-of-function underlies non-dominant congenital glaucoma with variable anterior segment dysgenesis and abnormal extracellular matrix
Aroca-Aguilar JD
Human Genetics 2020; 139: 1209-1231
91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Labbé A
Expert Opinion on Drug Safety 2021; 0: 1-14
91099 CPAMD8 loss-of-function underlies non-dominant congenital glaucoma with variable anterior segment dysgenesis and abnormal extracellular matrix
Corton M
Human Genetics 2020; 139: 1209-1231
91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Katsanos A; Meier-Gibbons F
Expert Opinion on Drug Safety 2021; 0: 1-14
91099 CPAMD8 loss-of-function underlies non-dominant congenital glaucoma with variable anterior segment dysgenesis and abnormal extracellular matrix
Ramírez AI; Alexandre-Moreno S
Human Genetics 2020; 139: 1209-1231
91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Irkec M; Boboridis KG
Expert Opinion on Drug Safety 2021; 0: 1-14
91099 CPAMD8 loss-of-function underlies non-dominant congenital glaucoma with variable anterior segment dysgenesis and abnormal extracellular matrix
García-Antón MT
Human Genetics 2020; 139: 1209-1231
91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Holló G
Expert Opinion on Drug Safety 2021; 0: 1-14
91099 CPAMD8 loss-of-function underlies non-dominant congenital glaucoma with variable anterior segment dysgenesis and abnormal extracellular matrix
Salazar JJ; Ferre-Fernández JJ
Human Genetics 2020; 139: 1209-1231
91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
García-Feijoo J
Expert Opinion on Drug Safety 2021; 0: 1-14
91099 CPAMD8 loss-of-function underlies non-dominant congenital glaucoma with variable anterior segment dysgenesis and abnormal extracellular matrix
Atienzar-Aroca R
Human Genetics 2020; 139: 1209-1231
91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Dutton GN
Expert Opinion on Drug Safety 2021; 0: 1-14
91099 CPAMD8 loss-of-function underlies non-dominant congenital glaucoma with variable anterior segment dysgenesis and abnormal extracellular matrix
Villaverde C
Human Genetics 2020; 139: 1209-1231
91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Baudouin C
Expert Opinion on Drug Safety 2021; 0: 1-14
91099 CPAMD8 loss-of-function underlies non-dominant congenital glaucoma with variable anterior segment dysgenesis and abnormal extracellular matrix
Iancu I; Tamayo A; Méndez-Hernández CD; Morales-Fernández L; Rojas B; Ayuso C; Coca-Prados M; Martinez-de-la-Casa JM; García-Feijoo J; Escribano J
Human Genetics 2020; 139: 1209-1231
